Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imraldi

- PMLiVE

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

Biotech company did not disclose the reason for the partnership's end

- PMLiVE

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

Collaborative trial will evaluate three anti-inflammatory drugs

- PMLiVE

Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma

Company aims to extend market reach

- PMLiVE

Biogen raises full year guidance after beating Q2 expectations

Key drug franchises boost total revenues in the quarter

Biogen Idec building

Biogen, Eisai take Alzheimer’s candidate BAN2401 into phase 3

Pivotal AHEAD 3-45 programme initiated this week

- PMLiVE

Biogen completes filing for highly-anticipated Alzheimer’s drug

FDA has 60 days to decide whether to accept filing for review

- PMLiVE

AbbVie suspends Kaletra patent rights as COVID-19 drug trials advance

Drug and vaccine trials pick up speed as virus spreads

Alzheimer’s: the search for a cure

Will Biogen’s aducanumab re-energise the hunt for pharma’s white whale?

- PMLiVE

Biogen joins COVID-19 efforts with $10m support fund

Funds will be used to address 'immediate critical needs'

- PMLiVE

EU grants approval for Venclyxto/Gazyvaro combo in CLL

Chemotherapy-free option for previously-untreated patients

- PMLiVE

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

Combination regimen didn't improve progression-free survival

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links